Document is current
Any future updates will be listed below
-
Authors
Ali, Hassan A.
Karasinska, Joanna M.
Topham, James T.
Johal, Danisha
Kalloger, Steve
Metcalfe, Andrew
Warren, Cassia S.
Miyagi, Anthony
Tao, Lan V.
Kevorkova, Maya
Chafe, Shawn C.
McDonald, Paul C.
Dedhar, Shoukat
Parker, Seth J.
Renouf, Daniel J.
Schaeffer, David F.
-
Funding
Funding for this research was provided by:
BC Cancer Foundation
Terry Fox Research Institute
Canadian Cancer Society Research Institute
- License Information
-
More Information
Article History
Received: 2 June 2024
Accepted: 26 September 2024
First Online: 3 October 2024
Declarations
:
: The PanGen (Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis; NCT02869802) trial were approved by the University of British Columbia Research Ethics Committee (REB# H14-00291). Written informed consent was obtained from each patient prior to tissue collection and PDO experiments.
: Not applicable.
: The authors declare no competing interests.
